Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System

摘要

Objective(s):Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 (⁹⁰Y) and lutetium-177 (¹⁷⁷Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy. In-house production with automated PRRT synthesis systems have clear advantages over manual methods resulting in increasing use in hospital-based radiopharmacies. We report on our one year experience with an automated radiopharmaceutical synthesis system.